Duncan Armour

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity

C. Gardner, Duncan Armour, David T. Beattie et al. · Regulatory Peptides · 1996 · 145 citations

G Protein-coupled Receptor, Medicine, Drug Discovery +9

Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”

Christopher Aquino, Duncan Armour, Judd Berman et al. · Journal of Medicinal Chemistry · 1996 · 101 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Glaxo Registry File +15

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

David A. Price, Duncan Armour, Marcel de Groot et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 76 citations · Full text

Molecular Pharmacology, Ccr5 Antagonist Maraviroc, Medicine +5

Enantioselective Synthesis of 3,6-Dihydro-1<i>H</i>-pyridin-2-ones:  Unexpected Regioselectivity in the Palladium-Catalyzed Decarboxylative Carbonylation of 5-Vinyloxazolidin-2-ones

Julian G. Knight, Simon W. Ainge, Andrew M. Harm et al. · Journal of the American Chemical Society · 2000 · 73 citations

Chemical Engineering, Uk Zeneca Pharmaceuticals, Engineering +13